Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL)

Annals of Oncology

Volumn 26, Issue 5, 2015, Pages 966-973

  Chihara, Dai ^a,b   Asano, N ^c   Ohmachi, K ^d   Nishikori, M ^e   Okamoto, M ^f   Sawa, M ^g   Sakai, R ^h   Okoshi, Y ⁱ   Tsukamoto, N ^j   Yakushijin, Y ^k   Nakamura, S ^c   Kinoshita, T ^b   Ogura, M ^l   Suzuki, R ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g ANJO KOSEI HOSPITAL   (Japan)

^h KANAGAWA CANCER CENTER   (Japan)

ⁱ UNIVERSITY OF TSUKUBA   (Japan)

^j GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l SUZUKA NATIONAL HOSPITAL   (Japan)

more..

Author keywords

CNS relapse; Ki 67; Mantle cell lymphoma; Risk factors

Indexed keywords

CYTARABINE; KI 67 ANTIGEN; METHOTREXATE; RITUXIMAB;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EVALUATION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; EPIDEMIOLOGY; INCIDENCE; JAPAN; KAPLAN MEIER METHOD; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; RECURRENT DISEASE; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; INCIDENCE; JAPAN; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929084900     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv074     Document Type: Article

References (26)

1. Swerdlow S, Campo E, Harris N et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer (IARC), 2008.
2. Chihara D, Ito H, Matsuda T et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 2014; 164: 536-545.
3. Vose JM. Mantle cell lymphoma: 2013 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 2013; 88: 1082-1088.
4. Dreyling M, Thieblemont C, Gallamini A et al. ESMO Consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24: 857-877.
5. Conconi A, Franceschetti S, Lobetti-Bodoni C et al. Risk factors of central nervous system relapse in mantle cell lymphoma. Leuk Lymphoma 2013; 54: 1908-1914.
6. Cheah CY, George A, Gine E et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol 2013; 24: 2119-2123.
7. Ferrer A, Bosch F, Villamor N et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008; 19: 135-141.
8. Romaguera JE, Fayad L, Rodriguez MA et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013-7023.
9. Oki Y, Ogura M, Kato H et al. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Sci 2008; 99: 179-184.
10. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
11. Fine JP. Regression modeling of competing crude failure probabilities. Biostatistics 2001; 2: 85-97.
12. Hoster E, Dreyling M, Klapper W et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558-565.
13. Hosein PJ, Maragulia JC, Salzberg MP et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol 2014; 165: 358-363.
14. Zucca E, Conconi A, Mughal TI et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003; 21: 20-27.
15. Rosenwald A, Wright G, Wiestner A et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185-197.
16. Katzenberger T, Petzoldt C, Holler S et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006; 107: 3407.
17. Tiemann M, Schrader C, Klapper W et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005; 131: 29-38.
18. Cheah CY, Herbert KE, O'Rourke K et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer 2014; 111: 1072-1079.
19. Kasamon YL, Jones RJ, Piantadosi S et al. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transplant 2005; 11: 93-100.
20. Lippens RJ, Winograd B. Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction. Pediatr Hematol Oncol 1988; 5: 115-124.
21. Goy A, Sinha R, Williams ME et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013; 31: 3688-3695.
22. Wang M, Fayad L, Wagner-Bartak N et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012; 13: 716-723.
23. Muscal JA, Sun Y, Nuchtern JG et al. Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemother Pharmacol 2012; 69: 943-947.
24. Warren KE, Goldman S, Pollack IF et al. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol 2011; 29: 324-329.
25. Rubenstein JL, Treseler PA, Stewart PJ. Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol 2011; 29: e595-e597.
26. de Jong D, Rosenwald A, Chhanabhai M et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007; 25: 805-812.